We are live on
!
Find out more
BCM
BML Capital Management Portfolio holdings
AUM
$156M
1-Year Est. Return
129.82%
This Fund
S&P 500
This Quarter
Est. Return
+22.99%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$111M
AUM Growth
-$4.51M
(-3.9%)
Cap. Flow
-$19M
Cap. Flow
% of AUM
-17.07%
Top 10 Holdings %
Top 10 Hldgs %
79.87%
Holding
38
New
7
Increased
5
Reduced
8
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$8.37M |
| 2 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
+$5.52M |
| 3 |
Quince Therapeutics
QNCX
|
+$2.2M |
| 4 |
Passage Bio
PASG
|
+$1.7M |
| 5 |
CalciMedica
CALC
|
+$388K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tilly's
TLYS
|
+$7.07M |
| 2 |
Abercrombie & Fitch
ANF
|
+$5.08M |
| 3 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
+$4.5M |
| 4 |
Disc Medicine
IRON
|
+$4.41M |
| 5 |
EMBK
Embark Technology, Inc. Common Stock
EMBK
|
+$3.61M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.2% |
| 2 | Consumer Discretionary | 5.18% |
| 3 | Technology | 2.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.8B
| $18.4M | 16.52% |
200,000
| – | – |
|
|
2
iShares 0-3 Month Treasury Bond ETF
SGOV
$97.5B
| $18.1M | 16.29% |
180,000
+55,000
| +44% | +$5.52M |
|
|
CYT
3
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $8.45M | 7.6% |
3,250,000
+103,704
| +3% | +$217K |
|
|
4
Atea Pharmaceuticals
AVIR
$377M
| $8.36M | 7.52% |
+2,236,239
| New | +$8.37M |
|
|
ADVM
5
DELISTED
Adverum Biotechnologies
ADVM
| $8.2M | 7.38% |
515,718
-191,000
| -27% | -$2.01M |
|
|
PRDS
6
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
| $6.86M | 6.17% |
3,791,633
-194,944
| -5% | -$356K |
|
|
TRML
7
DELISTED
Tourmaline Bio
TRML
| $6.08M | 5.47% |
200,000
+7,052
| +4% | +$180K |
|
|
LONA
8
LeonaBio Inc
LONA
$73.4M
| $5.5M | 4.95% |
186,491
| – | – |
|
|
CLYM
9
Climb Bio
CLYM
$720M
| $4.43M | 3.99% |
1,583,170
-75,000
| -5% | -$228K |
|
|
10
Abercrombie & Fitch
ANF
$4.33B
| $4.43M | 3.98% |
117,500
-178,278
| -60% | -$5.08M |
|
11
Astrotech Corp
ASTC
$15.1M
| $3.12M | 2.81% |
220,410
| – | – |
|
12
Oramed Pharmaceuticals
ORMP
$166M
| $3.04M | 2.74% |
850,000
-505,925
| -37% | -$1.62M |
|
|
13
Quince Therapeutics
QNCX
$18.3M
| $2.12M | 1.91% |
+7,059
| New | +$2.2M |
|
|
14
Passage Bio
PASG
$15.8M
| $1.94M | 1.74% |
102,938
+86,065
| +510% | +$1.7M |
|
15
Forte Biosciences
FBRX
$921M
| $1.8M | 1.62% |
69,403
| – | – |
|
16
Enliven Therapeutics
ELVN
$3.63B
| $1.52M | 1.36% |
74,232
-137,947
| -65% | -$2.79M |
|
|
ORKA
17
Oruka Therapeutics
ORKA
$5.01B
| $1.44M | 1.29% |
58,911
| – | – |
|
|
18
Tilly's
TLYS
$122M
| $1.34M | 1.2% |
190,518
-964,326
| -84% | -$7.07M |
|
19
Lisata Therapeutics
LSTA
$31.9M
| $902K | 0.81% |
243,839
| – | – |
|
20
Verrica Pharmaceuticals
VRCA
$95.5M
| $866K | 0.78% |
15,000
| – | – |
|
21
Surrozen
SRZN
$241M
| $802K | 0.72% |
97,272
-2,330
| -2% | -$21.9K |
|
22
Milestone Pharmaceuticals
MIST
$154M
| $777K | 0.7% |
272,500
+52,500
| +24% | +$198K |
|
23
Retractable Technologies
RVP
$20.7M
| $769K | 0.69% |
668,575
| – | – |
|
24
NextCure
NXTC
$25.1M
| $552K | 0.5% |
25,539
| – | – |
|
|
LENZ
25
LENZ Therapeutics
LENZ
$153M
| $396K | 0.36% |
21,756
| – | – |
|
Similar funds
AIS
BWM
TI
CFG
IWA
PFO
HCWM
BCM
BML Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, BML Capital Management held 38 positions worth $111M, down 3.9% from $116M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
BML Capital Management withdrew a net $19M in Q2 2023, closing 7 positions and reducing 8 holdings. Its most notable exit was Satsuma Pharmaceuticals, Inc. Common Stock, an estimated $4.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 53% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, BML Capital Management opened a new position in Atea Pharmaceuticals worth $8.36M.
- BML Capital Management's largest Q2 2023 buy was Atea Pharmaceuticals: 2,236,239 shares worth $8.36M.
- BML Capital Management added most to iShares 0-3 Month Treasury Bond ETF in Q2 2023, an estimated $5.52M increase.
- BML Capital Management's biggest Q2 2023 reduction was Tilly's, cutting an estimated $7.07M.
- BML Capital Management fully exited Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2023, selling an estimated $4.5M.
- BML Capital Management's ten largest holdings make up 80% of its $111M portfolio in Q2 2023.
- BML Capital Management opened 7 new positions and closed 7 in Q2 2023.
- BML Capital Management's portfolio value fell 3.9% quarter-over-quarter to $111M.
Based on BML Capital Management's 13F filing for Q2 2023, filed 24 Jul 2023.